TO THE EDITOR:
Although Weinberg and colleagues' study (1) is interesting and well-done, the negative results are not surprising. Among several possibilities for these results are the time frame for estimating risk for colorectal cancer (CRC), the magnitude of the risk, the 6-month interval for assessing screening uptake, and whether the genetic and environmental risk assessment had meaning to study participants.
With regard to the time frame for CRC risk, it seems that study participants were told about their lifetime risk for this condition. Knowing about lifetime CRC risk may motivate persons or patients less-particularly in the short term (6 months or perhaps 1 year)-than would knowing about a current or near-term risk. In general, persons want to know what they need to do now or in the near term in response to learning about "risk." Because CRC prevalence is so low and advanced precancerous polyps have become the target lesion of screening, telling persons about their current risk for advanced neoplasia (that is, the combination of CRC and advanced polyps) could result in screening uptake sooner and to a greater degree or extent than telling them their lifetime CRC risk (a future risk).
The perception of a low magnitude of risk may be another reason for inaction in the short term. Average lifetime risk for CRC is approximately 5% (or 1 in 20). Even if the genetic and environmental risk assessment suggests a doubling of lifetime risk, that risk is still just 10%, which many would interpret as having a 90% chance of not getting CRC. This interpretation supports inertia to avoid screening, especially in the short term. In contrast, telling persons that they have a 20% to 25% (1 in 4 or 1 in 5) chance of having an advanced, precancerous polyp present "now" (because of several phenotypic features) may be a greater motivator to get screened in the short term. Given a future risk for CRC-whether elevated or not-allowing just 6 months to assess screening uptake likely contributed to the negative results.
Finally, whether persons understand and accept the results of genetic and environmental risk assessment may be questioned. Persons can probably comprehend and relate better to older age, male sex, cigarette smoking, a family history of CRC, overweight status, and other phenotypic features as risk factors than they can to polymorphic variants of methylenetetrahydrofolate reductase and low serum folate levels as increasing their risk for CRC and, thus, as motivators toward CRC screening. 
3D-CAM

TO THE EDITOR:
We read Marcantonio and colleagues' article (1) with great interest. The early recognition of delirium across all hospital settings is an important factor in patient safety and care. Nurses caring for patients have the best opportunity to recognize a disorder that fluctuates over time, such as this condition. The ultimate goal of having a brief and accurate tool to aid nurses in the early detection of delirium without adding excess burden to ever-increasing nurse charting time is important. Marcantonio and colleagues did, indeed, show that the 3D-CAM (3D-Confusion Assessment Method) decreases the time to complete delirium assessment to 3 minutes while maintaining high sensitivity and specificity.
In the Discussion section, the authors comment, "We currently have no brief instrument that is well-suited for widespread use across clinical settings." We argue that the Nursing Delirium Screening Scale (Nu-DESC) is such an instrument. This tool is an observational, 5-item delirium screening scale that can be completed in approximately 1 minute (2). When studied in medical (2), surgical (3), and intensive care units, the Nu-DESC took less time and had clinically similar sensitivity and specificity to other instruments, such as the CAM, and showed efficacy in identification of hypoactive delirium. The Nu-DESC has been successfully implemented hospital-wide among medical-surgical patients as a major part of a delirium protocol at our institutions (4) . Nursing staff has favored this delirium screening tool because of its short administration time and ease of use. The ability to quickly train nurses to use it has also been viewed as an advantage. However, the Nu-DESC is not perfect and problems with accuracy of assessment by nurses despite high accuracy by investigators have been reported (5) .
In our experience, for a delirium screening test to accepted by nurses, it must be quick and accurate and perceived as valuable. The difference between 1 minute and 3 minutes can become quite important when applied to multiple patients cared for during each shift. If the delirium assessment tool does not have workflow efficiency, then sustainability of its use is jeopardized. The Nu-DESC should be considered for broader clinical use in hospitals and should certainly be considered in any future comparative research trials.
IN RESPONSE: Dr. Wilford and colleagues describe their experience with the Nu-DESC (1), a brief delirium screening instrument that assesses 5 features: disorientation, inappropriate behavior, inappropriate communication, illusions/hallucinations, and psychomotor retardation. Each feature is rated 0, 1, or 2, and a total score of 2 or higher out of 10 is considered a positive screen for delirium. Of note, Nu-DESC scoring is based on routine nursing observations and requires no formal interviewing or cognitive testing. Therefore, it can be completed very quickly-in 1 minute or less. In the references that Dr. Wilford and colleagues provide, this tool has excellent test characteristics relative to a reference standard. However, other publications report worse performance; for example, a recent study of surgical patients reported sensitivities between 29% and 32% (2) , indicating that 7 of 10 cases of delirium were missed.
The key to delirium assessment is the quality of data that go into determining the presence or absence of core diagnostic features of delirium. In modern hospital care, physicians and nurses do not routinely interact with patients in ways that reliably elicit delirium features. For example, when the CAM algorithm was completed by nurses solely on the basis of observations from routine care, its sensitivity was 30% relative to a reference standard (3) . Information provided by structured testing is essential, particularly for patients with hypoactive delirium.
The 3D-CAM incorporates patient symptom probes (such as "Have you felt confused today?") and cognitive testing (such as stating the days of the week backward) in addition to observational items. Structured testing enhances sensitivity so that cases will not be missed, ensures that all key features of delirium are assessed, and enhances reliability by collecting a uniform set of data. It also provides an objective measure of cognitive function that facilitates assessment of change in future days. Defining a brief yet informative set of cognitive items is a key contribution of the 3D-CAM.
The 3D-CAM, when administered in full, can be completed in 3 minutes. Using skip patterns or up-front screening items may shorten the 3D-CAM further while retaining excellent performance. Our group is actively developing and testing methods to enhance the feasibility of delirium identification in clinical practice. For the time being, we urge clinicians to incorporate structured testing, such as the items in the 3D-CAM, into their routine assessment of delirium. should be used to avoid a recurrence of nephrolithiasis. If hypercalciuria is present, thiazide diuretics obviously should be used. However, use of thiazides in the presence of uricosuria may be counterproductive. Allopurinol should be used with uricosuria, but allopurinol and citrates also may be successfully used in the absence of hypercalciuria or uricosuria.
Edward R. Marcantonio, MD, SM
Obese patients with type 2 diabetes frequently have acidic urine due to hyperinsulinemia, inducing a decrease in ammonia production in the proximal tubule and sodium clearance. The resulting lower urine pH can cause uric acid to "come out" of solution and crystallize (2) . Although most calculi in obese participants with type 2 diabetes are composed of calcium oxylate, the proportion of uric acid stones is higher than in control participants (35.8% vs. 11.3%) (3). Normal uric acid excretion is less than 800 mg/d, but uric acid can crystallize at levels as low as 200 mg/day in the presence of acidic urine. In this situation, the most effective therapies to prevent stone formation are allopurinol to reduce uricosuria and citrates to neutralize the acidic urine.
In the absence of an analysis of a previous stone or hypercalciuria, a low urine pH should suggest that therapy with allopurinol, a citrate, or both will decrease the formation of calculi (4). TO THE EDITOR: Qaseem and colleagues' (1) recommendation to drink at least 2 L of fluid per day and use thiazide diuretics, citrate, or allopurinol when fluids alone are insufficient mirror a recent guideline released by the American Urological Association. However, several features of the American College of Physicians' recommendations disagree with those of the American Urological Association. For example, Qaseem and colleagues do not recommend baseline evaluation of stone composition or 24-hour urine analysis for stone risk factors. Kidney stone analysis by infrared spectroscopy is relatively inexpensive; very precise; and, in our opinion, essential to properly diagnose the form of kidney stone disease. A thi-azide diuretic would not be helpful for a patient with uric acid kidney stones or someone with cystinuria, both of which can be determined by stone analysis alone. Furthermore, 24-hour urine analysis can help to guide logical therapeutic choices and specific dietary advice for an individual patient. For example, pharmacotherapy may not help persons in whom a very low urine volume is the only major risk factor and those with enteric hyperoxaluria need specific therapy geared toward dietary measures to reduce oxalate loads. In these cases, allopurinol or thiazide would probably not have any benefit.
David S.H. Bell, MD
Although rare, certain genetic conditions associated with stone disease, such as primary hyperoxaluria, can be diagnosed by extreme abnormalities noted on 24-hour urine studies. Early intervention in such conditions can slow disease progression. Urine studies would be diagnostic and extremely helpful for management of patients in only a few situations and show potential flaws in the minimalistic approach recommended by Qaseem and colleagues. Like many disorders, kidney stone disease is complicated with a variable phenotype. The guideline does little to acknowledge or highlight these issues. Current studies indicate that fewer than 10% of persons with kidney stone disease have a full metabolic workup to prevent further stone formation (2). The approach implied by Qaseem and colleagues' guideline will do little to increase the rate of appropriate metabolic evaluations or help to abate the increasing incidence of stone disease in the United States (3). In contrast, the American Urological Association guideline seems to be more balanced and, in general, contain more useful advice for a physician faced with a patient who has recurrent kidney stones. IN RESPONSE: Dr. Bell raises an important issue and suggests that the American College of Physicians should offer guidance on what drugs to use under specific circumstances. We acknowledge in the guideline that biochemistry suggests a link between the mode of action of the various drugs and stone type. However, results were mixed about whether baseline biochemistry measures predicted treatment effectiveness for reducing the risk for stone recurrence or for the efficacy of dietary or pharmacologic treatments compared with placebo or controls for recurrent stone outcomes. In addition, no randomized, controlled trials compared risk for stone recurrence according to follow-up biochemistry measures or changes from pretreatment biochemistry values. A post hoc analysis of 1 randomized, controlled trial described in the evidence review on which this guideline was based (1) suggested that the benefit of allopurinol treatment was limited to patients with baseline hyperuricemia or hyperuricosuria. However, this finding was the only available evidence from a randomized, controlled trial linking stone biochemistry to recurrent stone outcomes, it was only for 1 drug, and the analysis was done post hoc. As we point out in the guideline, we are aware that many physicians do select medications on the basis of stone type (for example, allopurinol for uric acid stones) and we do not discourage that practice.
Drs (1) have presented a particularly interesting article about the position of models in clinical practice guidelines. Indeed, models can bridge the gap between direct evidence provided from randomized, controlled trials (RCTs) or observational studies and questions raised in daily practice. To estimate the degree that models are used in the development of current guidelines, we evaluated the list of the 100 most cited guidelines of the National Guideline Clearinghouse (www.guideline.gov) that we had identified for a previous study. The number of citations was extracted from the Thomson Reuters Web of Science (formerly ISI Web of Science). The search of the most cited guidelines was done to select those most influential in clinical practice and research development. Using the results of that search, we did a secondary analysis with a major outcome being the degree of incorporation of mathematical models in guideline justification. Surprisingly, we found that 54% of these guidelines use conclusions derived from modeling studies to support their recommendations.
This observed magnitude of models in the development of practice guidelines and their expected growing use in the future raises a need for an objective (to the extent possible) assessment of their merits in terms of internal validity and reproducibility. Habbema and colleagues mention reasonable criteria for the assessment of the credibility of models. However, so far, consensus statements have mostly focused on the quality of presentation and reporting, such as the recently published Consolidated Health Economic Evaluation Reporting Standards checklist for cost-effectiveness studies (2), whereas statements for the assessment of the internal validity of the reporting outcomes, similar to the Cochrane Collaboration tool for RCTs (3) or the Newcastle-Ottawa Scale for observational studies (4), are currently lacking. Furthermore, given that the model on which a guideline is based should be calibrated to every meaningful measurement that is published, there might be a need for a systematic and predefined verification and update of included models at fixed intervals separate from the overall assessment of the guideline.
In summary, more than 50% of the examined guidelines of the National Guideline Clearinghouse included results derived from mathematical models to support their recommendations. Admittedly, models can be of substantial help in guiding daily clinical practice about questions that cannot be answered directly by conventional RCTs or observational studies. However, an objective assessment of their internal validity should be established. Otherwise, we risk undermining the high-quality data provided by RCTs.
Ioannis M. Zacharioudakis, MD Fainareti N. Zervou, MD Eleftherios Mylonakis, MD, PhD
Warren Alpert Medical School of Brown University Providence, Rhode Island IN RESPONSE: We welcome Dr. Zacharioudakis and colleagues' comment about the effect of internal validity on model quality and the corresponding guideline. Internal validity, or calibration, refers to successful fitting of the model to the results of primary studies (1). Models with high internal validity are necessary to reliably inform guideline developers. Zacharioudakis and colleagues' statements reaffirm our remark that consensus standards for model quality have not been established.
We believe that their suggestion that models should be calibrated to "every meaningful measurement that is published" is not realistic. Given the enormous amount of published meaningful measurements, judgments on data relevance and quality will be required. We believe that calibration should be targeted to the most relevant high-quality data from randomized and observational studies. For example, if a U.S. screening guideline is under consideration, then calibration to U.S. population data might be preferred and could yield different estimates of key model parameters (2) . Transparency in how data are selected and incorporated is required; so is identifying plausible alternative calibration targets that can be used for external validation purposes.
Zacharioudakis and colleagues suggest using fixed time intervals for updating models. We agree that updating models is important but believe that updates should be based on the emergence of important new data rather than fixed time intervals. For example, after the publication of the results of sigmoidoscopy screening trials, guideline groups and modelers discussed the need for recalibrating colorectal cancer models. These data were too important to delay recalibration. On the other hand, if no crucial new data are published during the preset time interval, waiting can save time and resources without losing guideline relevance. Because many guideline groups do update recommendations on a timederived basis, this practice may alternatively be a pragmatic opportunity to assess the need of a model update.
We are encouraged to learn that more than one half of the most cited guidelines incorporated modeling studies. However, of greater importance is determining whether "model use" correlates with our recommended favorable condition for model involvement; namely, that strong primary evidence existed to inform the model but that critical gaps remained between the evidence and the questions that the guideline developers addressed. This circumstance will provide guideline users with increased confidence when implementing model-based guideline recommendations. Irrespective, better internal-and external-model validity will enhance the quality of model results; resulting guidelines; and, ultimately, population health.
J. Dik F. Habbema, PhD
Erasmus MC University Medical Center Rotterdam, the Netherlands Chikungunya TO THE EDITOR: Hamer and Chen's article (1) failed to mention and address the incidence of chikungunya virus in Puerto Rico, although the Centers for Diseases Control and Prevention eloquently did so in the Morbidity and Mortality Weekly Report (2) . The first locally acquired, laboratory-confirmed case of chikungunya virus was detected in Puerto Rico in early May 2014, and 10 201 suspected cases (282 per 100 000 residents) had been reported by 12 August 2014. Certainly, there have been and will be implications locally in terms of public health. However, because of the known shunt between Puerto Rico and the mainland United States, U.S. physicians should become more aware of chikungunya virus when advising someone who will be traveling to Puerto Rico or treating an ill patient who has come from there.
William Rodriguez-Cintron, MD Veterans Affairs Caribbean Healthcare System San Juan, Puerto Rico TO THE EDITOR: We read Hamer and Chen's article (1) with great interest. However, chronic chikungunya arthritis can persist for months after infection (2, 3) . Among 47 travelers returning from the Indian Ocean islands, including Comoros, Mayotte, Mauritius, the Seychelles, and Ré union Island, followed for 14 months, late (developing after the 10th day) arthropathy-defined by the presence of at least 1 of the following symptoms: symmetric oligo-or polyarthritis accompanied by morning stiffness, nonspecific edema or tenosynovitis, or worsening of mechanical pain in a preexisting injured joint or bone-was identified in 38 persons (2) . In another series of 21 cases of newly diagnosed chikungunya virus with a mean follow-up of 2 years, all patients fulfilled the American College of Rheumatology's criteria for rheumatoid arthritis, with symptoms starting from the onset of viral infection to rheumatoid arthritis diagnosis (3).
Our department recently treated a patient with confirmed chikungunya virus who returned to Canada and presented with inflammatory polyarthritis after travelling to the Dominican Republic and Jamaica. The patient still had joint pain, 1 of the initial symptoms, after 3 months. We pursued work-up for a connective tissue disease. Initial antinuclear antibody titers were 1:80 in a speckled pattern persisting to 1:160 a month later, and initial anti-double-stranded DNA levels were 38.7 IU/mL; however, results of repeated measurement of antidouble-stranded DNA titers were normal by Farr assay. Rheumatoid factor and anticyclic citrullinated peptide antibodies were not present. Whether the virus can trigger an autoimmune event remains unknown.
The mainstay treatment in the acute phase is analgesics or nonsteroidal anti-inflammatory drugs, as Hamer and Chen describe, and allowing some time before considering starting immunosuppressive therapy. However, reports are limited about resolution of symptoms by treating the chronic arthritic phase with hydroxychloroquine, methotrexate, or steroids (3, 4) . Research is ongoing on the mechanism of ␣ virus-related arthritis. Some data suggest that the presence of chikungunya in synovial macrophages triggers release of proinflammatory mediators (interleukin-10 and interferon-␣), leading to activation of matrix metalloprotease, induction of apoptosis, and fibroblast hyperplasia. These findings obviously suggest some similarities between the mechanism of chikungunya arthritis and rheumatoid arthritis (5). In conclusion, consider work-up for a connective tissue disease and follow-up in patients with chikungunya virus with prolonged arthralgia, arthritis, or both. Because of the large numbers of islands and countries affected by this widespread outbreak, our article on chikungunya virus in the Americas was unable to include a comprehensive list of all locations with autochthonous transmission (1); however, the Pan American Health Organization regularly provides updated case numbers and incidence rates for each island and country (2) . As of 20 February 2015, Puerto Rico has reported 24 714 suspected and 4302 confirmed cases, with an incidence rate of 787 cases per 100 000 persons. According to the Pan American Health Organization, the chikungunya virus outbreaks in the Dominican Republic and the French part of Saint Martin are even more dramatic, with more than 500 000 suspected cases in the former and an incidence rate of 17 016 cases per 100 000 persons in the latter (2) . Because of the high volume of travel between the United States and all infected areas, it is imperative that we raise the awareness of clinicians practicing in the contiguous United States about chikungunya virus in the Americas-all Caribbean islands and most countries in Central and South America.
We appreciate Drs. Al-Araimi and Mittoo's comments about the similarity in presentation between chikungunya arthritis and rheumatoid arthritis and their recommendation that work-up is warranted for connective tissue disease in patients diagnosed with chikungunya virus who have persistent or recurrent arthritis. After the chikungunya virus epidemic in La Ré union in 2005, a cohort study of 147 patients with chikungunya virus found that 57% reported rheumatic symptoms at 15 months (nearly two thirds with persistent symptoms and one third with recurrent or relapsing symptoms) (3). These findings are similar to those of the patient that Drs. Al-Araimi and Mittoo describe.
As Drs. Al-Araimi and Mittoo note, whether chikungunya virus triggers an autoimmune process is not yet known; however, some immunologic findings suggest inflammatory mechanisms (4) . In patients with chikungunya virus who are later diagnosed with rheumatoid arthritis, the usefulness of therapy with disease-modifying antirheumatic drugs-such as methotrexate, tumor necrosis factor blockers, hydroxychloroquine, and corticosteroids-has not yet been established (5) . Finally, because patients with persistent or relapsing arthralgia or arthritis may present to rheumatologists and primary care providers for evaluation, specialists should remain vigilant about assessing for chikungunya virus. Longitudinal natural history studies and randomized, controlled trials of interventions for patients with this condition who have persistent arthritis are critically needed. 
